ICON has approximately 41,150 employees in 102 locations in 54 countries as at March 31, 2024. In addition to its own global network of offices, ICON can provide service delivery in a total of 93 countries globally, through locally based staff who work from home, and partnerships with local third-party providers. ICON offers a broad range of specialised solutions to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our solutions span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop innovative technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

• Quarter one 2024 revenue of $2,090.4 million. This represents an increase of 5.7% on prior year revenue or 5.4% on a constant currency basis.
• Full year revenue in 2023 was $8,120.2 million. This represents a year on year increase of 4.9% on a reported basis and 4.6% on a constant currency basis.
• 2024 financial guidance of revenue in the range of $8,480 - $8,720 million, representing a year over year increase of 4.4% to 7.4%, and adjusted earnings per share* in the range of $14.65 - $15.15, representing a year over year increase of 14.5% to 18.5%.